跳转至内容
Merck
CN

H0513

Sigma-Aldrich

七(2,6-二-O-甲基)-β-环糊精

别名:

DM-β-CD, DM‐β‐CyD, 七-(2,6-O-二甲基)-β-环糊精, 2,6-二-O-甲基-β-环糊精, 二甲基 β-环糊精

登录查看公司和协议定价

关于此项目

经验公式(希尔记法):
C56H98O35
CAS Number:
分子量:
1331.36
Beilstein:
1679144
MDL编号:
UNSPSC代码:
12352005
PubChem化学物质编号:
NACRES:
NA.22
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

synthetic

质量水平

表单

powder

SMILES字符串

COC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](OC)[C@H](O[C@@H]3COC)O[C@H]4[C@H](O)[C@@H](OC)[C@H](O[C@@H]4COC)O[C@H]5[C@H](O)[C@@H](OC)[C@H](O[C@@H]5COC)O[C@H]6[C@H](O)[C@@H](OC)[C@H](O[C@@H]6COC)O[C@H]7[C@H](O)[C@@H](OC)[C@H](O[C@@H]7COC)O[C@H]8[C@H](O)[C@@H](OC)[C@H](O[C@@H]8COC)O[C@H]1[C@H](O)[C@H]2OC

InChI

1S/C56H98O35/c1-64-15-22-36-29(57)43(71-8)50(78-22)86-37-23(16-65-2)80-52(45(73-10)30(37)58)88-39-25(18-67-4)82-54(47(75-12)32(39)60)90-41-27(20-69-6)84-56(49(77-14)34(41)62)91-42-28(21-70-7)83-55(48(76-13)35(42)63)89-40-26(19-68-5)81-53(46(74-11)33(40)61)87-38-24(17-66-3)79-51(85-36)44(72-9)31(38)59/h22-63H,15-21H2,1-14H3/t22-,23-,24-,25-,26-,27-,28-,29+,30+,31+,32+,33+,34+,35+,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-/m1/s1

InChI key

QGKBSGBYSPTPKJ-UZMKXNTCSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

七(2,6-二-O-甲基)-β-环糊精是一种亲水性环糊精衍生物,有效溶解类固醇激素、维生素A、E和K等亲脂性药物,可用于提高难溶性药物化合物的溶解度和生物利用度。

应用

七(2,6-二-O-甲基)-β-环糊精可用于:
  • 通过电子顺磁共振(EPR)光谱法测定其与各种手性氮氧化物的对映体对形成的复合物的平衡常数。
  • 通过X射线衍射(XRD)研究其与丙烯酸正丁酯和丙烯酸异冰片酯形成的复合物的晶体结构。
  • 作为手性选择剂,用于通过毛细管区带电泳法分离安非他命相关药物。

涉及的反应物:
  • 包合物的理化研究
  • 与重组膜蛋白的探测扩散和单分子相互作用
  • 与胶束的相互作用导致胶束破裂
  • 研究细胞转运,用作细胞渗透促进剂
  • 药物的理化和生物药剂学改进 ,特别是溶解和稳定性
  • 与胆固醇的相互作用

分析说明

杂质为过度甲基化类似物,主要是六(2,6-二-O-甲基)-(2,3,6-三-O-甲基)-β-环糊精。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

F Hirayama et al.
Journal of pharmaceutical sciences, 88(10), 970-975 (1999-10-09)
Acetyl groups were introduced to the hydroxyl groups of heptakis(2, 6-di-O-methyl)-beta-cyclodextrin (DM-beta-CyD), and the resulting heptakis(2,6-di-O-methyl-3-O-acetyl)-beta-CyD (DMA-beta-CyD) was evaluated for the inclusion property and hemolytic activity. It was confirmed by means of NMR and mass spectroscopies that in the DMA-beta-CyD
Z Aigner et al.
Journal of pharmaceutical and biomedical analysis, 57, 62-67 (2011-09-17)
The steps of formation of an inclusion complex produced by the co-grinding of gemfibrozil and dimethyl-β-cyclodextrin were investigated by differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD) and Fourier transform infrared (FTIR) spectroscopy with curve-fitting analysis. The endothermic peak at
Fernanda Pérez-Cruz et al.
Bioorganic & medicinal chemistry, 17(13), 4604-4611 (2009-05-26)
Four different 5-nitroindazole derivatives (1-4) and its inclusion with Heptakis(2,6-di-O-methyl)-beta-cyclodextrin (DMbetaCD) were investigated. The stoichiometric ratios and stability constants describing the extent of formation of the complexes were determined by phase-solubility measurements obtaining in all cases a type-A(L) diagram. Also
Paola Franchi et al.
Journal of the American Chemical Society, 126(13), 4343-4354 (2004-04-01)
EPR spectroscopy has been employed to investigate the formation of complexes between heptakis-(2,6-O-dimethyl)-beta-cyclodextrin (DM-beta-CD) and different enantiomeric pairs of chiral nitroxides of general structure PhCH2NO.CH(R)R'. Accurate equilibrium measurements of the concentrations of free and included radicals afforded the binding constant
Fei Liu et al.
Chemical & pharmaceutical bulletin, 60(12), 1479-1486 (2012-12-05)
Thienorphine hydrochloride (ThH) is a highly insoluble and readily metabolized partial-opioid agonist. It is used for the treatment of pain and heroin addiction. This study aimed to formulate and evaluate sublingual delivery systems containing ThH. Dimethyl-β-cyclodextrin (DM-β-CD) can enhance the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持